Welcome to our dedicated page for bioAffinity Technologies Warrant news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Technologies Warrant stock.
bioAffinity Technologies, Inc. addresses a critical need to find cancer early and treat cancer specifically. The company develops tests and therapies to detect and treat cancer at the cellular level. Their first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has the potential to dramatically increase overall diagnostic accuracy, leading to increased survival, fewer unnecessary invasive procedures, and lower patient anxiety and medical costs.
bioAffinity Technologies Inc. focuses on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment. They develop proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. CyPath Lung is their noninvasive test for the detection of early-stage lung cancer.
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the appointment of Jamie Platt, Ph.D., to its Board of Directors, effective Dec. 1, 2023. Dr. Platt brings two decades of experience in diagnostic technologies and has been instrumental in two M&A exits for diagnostic companies in 2022, resulting in a combined value of nearly $1 billion. She has extensive experience in expanding product market share in the diagnostics market. Dr. Platt's appointment is expected to drive bioAffinity's growth and success, particularly in commercializing CyPath® Lung, their noninvasive test for the early detection of lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. The CMS payment determination is a major milestone that facilitates reimbursement by both Medicare and private payers, making the test more attractive to physicians and their patients at high risk for lung cancer. The test showed 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients with small lung nodules less than 20 millimeters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
-
Rhea-AI Summary
BioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced that David Elzi, Ph.D., has been named to the Membership Committee of the American Society for Cell Biology (ASCB). ASCB is an international organization of cell biologists dedicated to advancing scientific discovery and improving education. Dr. Elzi will host a roundtable at Cell Bio 2023 to discuss transferable skills for transitioning into the biotech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
News
Rhea-AI Summary
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) launches a campaign with the American Cancer Society to increase lung cancer screening in Texas. The 'Power of Three' campaign aims to support local programs and emphasizes the importance of joining forces in the fight against lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
-
News
Rhea-AI Summary
BIAF - bioAffinity Technologies, Inc. reported financial results for the third quarter of 2023 and provided a business update. The company's subsidiary acquired Village Oaks Pathology Services, and CMS released a preliminary payment decision for CyPath® Lung. The U.S. Department of Defense purchased CyPath® Lung tests for an observational study. Revenue for the third quarter of 2023 increased to $298,484, and net loss was $2.3 million. The company expects to generate between $2.1 and $2.3 million in net revenues for 2023 and between $8.4 and $9.0 million over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
-
Rhea-AI Summary
bioAffinity Technologies, Inc. has appointed Dallas J. Coleman as National Director of Sales. Coleman has over 15 years of experience in medical sales and marketing. He will be responsible for leading the CyPath® Lung sales team and sourcing new business opportunities. His expertise is expected to help drive the expansion of their pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
Rhea-AI Summary
bioAffinity Technologies, Inc. CEO Maria Zannes to present corporate update at Dawson James Small Cap Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
bioAffinity Technologies acquires Precision Pathology Services to support commercialization of CyPath® Lung test. The acquisition cost $3.5 million in cash and stock. The transaction aims to accelerate market uptake, support FDA pivotal trial, and develop additional tests. Precision Pathology offers a range of laboratory services. Dr. Roby Joyce joins bioAffinity's board of directors. Conference call at 4:30 p.m. ET today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
-
Rhea-AI Summary
bioAffinity Technologies to present corporate update and hold meetings with investors at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
News
Rhea-AI Summary
bioAffinity Technologies reports financial results for Q2 2023 and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
FAQ
What is the current stock price of bioAffinity Technologies Warrant (BIAFW)?
The current stock price of bioAffinity Technologies Warrant (BIAFW) is $0.8689 as of November 18, 2024.
What is the focus of bioAffinity Technologies, Inc.?
The company focuses on developing tests and therapies to detect and treat cancer at the cellular level, with a particular emphasis on noninvasive diagnosis of early-stage cancer and diseases of the lung.
What is CyPath Lung?
CyPath Lung is a noninvasive test developed by bioAffinity Technologies, Inc. for the detection of early-stage lung cancer, aiming to increase overall diagnostic accuracy and improve patient outcomes.
bioAffinity Technologies, Inc. Warrant
Nasdaq:BIAFW
BIAFW Rankings
BIAFW Stock Data
11.49M
Diagnostics & Research
Services-commercial Physical & Biological Research
United States of America
SAN ANTONIO